Luca Pasquini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4063927/publications.pdf

Version: 2024-02-01

361045 360668 1,530 36 20 35 citations h-index g-index papers 37 37 37 3067 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Agile workflow for interactive analysis of mass cytometry data. Bioinformatics, 2021, 37, 1263-1268.	1.8	8
2	Skeletal Muscle Subpopulation Rearrangements upon Rhabdomyosarcoma Development through Single-Cell Mass Cytometry. Journal of Clinical Medicine, 2021, 10, 823.	1.0	4
3	qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets. Bioinformatics, 2020, 36, 5086-5092.	1.8	3
4	Platelet and megakaryocyte CD40L expression in \hat{l}^2 -Thalassemic patients. Thrombosis Research, 2020, 189, 108-111.	0.8	1
5	Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells. Frontiers in Oncology, 2020, 10, 621458.	1.3	29
6	The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica, 2019, 104, 973-985.	1.7	31
7	Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic molecules. Journal of Experimental and Clinical Cancer Research, 2018, 37, 245.	3. 5	104
8	Renal cancer: new models and approach for personalizing therapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 217.	3 . 5	17
9	Cell Propagation of Cholera Toxin CTA ADP-Ribosylating Factor by Exosome Mediated Transfer. International Journal of Molecular Sciences, 2018, 19, 1521.	1.8	3
10	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel, Switzerland), 2018, 5, 16.	0.7	123
11	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts <i>in vitro</i> . Oncotarget, 2017, 8, 32550-32565.	0.8	47
12	PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response. Journal of Hematology and Oncology, 2016, 9, 33.	6.9	5
13	Conditioned medium from human umbilical vein endothelial cells markedly improves the proliferation and differentiation of circulating endothelial progenitors. Blood Cells, Molecules, and Diseases, 2016, 61, 58-65.	0.6	14
14	Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. Journal of Translational Medicine, 2016, 14, 56.	1.8	148
15	Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells. PLoS ONE, 2015, 10, e0126968.	1.1	17
16	SCD5â€induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. Journal of Pathology, 2015, 236, 315-325.	2.1	34
17	Human cord blood-derived hemogenic endothelium generates mast cells. Blood Cells, Molecules, and Diseases, 2015, 54, 195-197.	0.6	0
18	The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis. Oncotarget, 2015, 6, 19671-19684.	0.8	11

#	Article	IF	CITATIONS
19	Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines. PLoS ONE, 2014, 9, e94438.	1.1	33
20	A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells. PLoS ONE, 2012, 7, e35073.	1.1	41
21	MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias. Blood Cancer Journal, 2011, 1, e26-e26.	2.8	50
22	Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors. International Journal of Oncology, 2010, 36, 707-13.	1.4	4
23	The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells, Molecules, and Diseases, 2010, 45, 86-92.	0.6	133
24	PLZF-mediated control on c-kit expression in CD34+ cells and early erythropoiesis. Oncogene, 2009, 28, 2276-2288.	2.6	24
25	Discovery of a new family of bis-8-hydroxyquinoline substituted benzylamines with pro-apoptotic activity in cancer cells: Synthesis, structure–activity relationship, and action mechanism studies. European Journal of Medicinal Chemistry, 2009, 44, 558-567.	2.6	46
26	High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. Cancer Letters, 2009, 282, 214-228.	3.2	24
27	A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nature Cell Biology, 2008, 10, 788-801.	4.6	214
28	Effective erythropoiesis and HbF reactivation induced by kit ligand in \hat{l}^2 -thalassemia. Blood, 2008, 111, 421-429.	0.6	17
29	A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecologic Oncology, 2007, 105, 481-492.	0.6	35
30	Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 635-655.	2.2	47
31	Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells, Molecules, and Diseases, 2006, 37, 218-225.	0.6	22
32	Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. European Respiratory Journal, 2006, 27, 529-541.	3.1	180
33	Apotosis-based therapies for hematological malignancies. Drugs of the Future, 2005, 30, 707.	0.0	1
34	Immunophenotypic Features of Acute Myeloid Leukemias Overexpressing the Interleukin 3 Receptor Alpha Chain. Leukemia and Lymphoma, 2004, 45, 1511-1517.	0.6	17
35	Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia, 2004, 18, 1864-1871.	3.3	42
36	In vitro assays of tumor chemosensitivity and chemoresistance. Drugs of the Future, 2004, 29, 1035.	0.0	1